Amakem banks €18M for ophthalmology drug studies

The Belgian biotech Amakem has raised €18 million ($25.2 million) in an impressive A round for its ophthalmology work. The biotech says it has enough money to get its lead candidate--a glaucoma drug called AMA0076--to clinical proof-of-concept. The round was led by Forbion Capital Partners and included Crédit Agricole Private Equity, Vesalius BioCapital, as well as the existing investors LRM, PMV and Life Sciences Research Partners. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.